Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Business Update & new Development Agreement signed

16 Oct 2008 07:00

RNS Number : 9551F
Oxford Advanced Surfaces Group PLC
16 October 2008
Β 

ο»Ώ

16 October 2008

OxfordΒ Advanced Surfaces Group PLC (the 'Company')

Business Update and new Development Agreement signed

Oxford Advanced Surfaces Group plc announces the signing of its first development agreement in the biomedical sector. The group has been engaged by aΒ European technology innovator working on novel medical devices in the field of gastroenterology.Β 

TheΒ Company is building aΒ development portfolioΒ across a broad range of applications and sectors, primarily through JointΒ Development AgreementsΒ ("JDAs")Β with leading players inΒ a variety ofΒ markets butΒ also advancing some in-house proofsΒ of concept inΒ selected applications.Β EachΒ ofΒ theseΒ projects, if they reach the market and are commercially successful, wouldΒ representΒ aΒ significant revenue and profitΒ opportunity forΒ both the customer and the Company.

Β 

With this new project we areΒ nowΒ actively engagedΒ inΒ elevenΒ  specificΒ  developmentΒ  programmes.Β  EightΒ of theseΒ areΒ in sectorsΒ suchΒ asΒ industrialΒ materials, consumer goods, electronicsΒ and now biomedical. AΒ furtherΒ three areΒ in-house development applications of the Ontoβ„’ technology for use in photovoltaicΒ devicesΒ and solid state lighting. AllΒ of these programmes are in Stage 1 (Development of Materials). Whilst we expect a number of these projects to progress to Stage 2 (Process Development & Manufacturing Trials) some attrition will naturally occur.Β 

In addition we have aΒ substantialΒ pipeline of opportunitiesΒ awaiting Initial Assessment or Proof of Concept ("PoC"). Many ofΒ these companiesΒ are globalΒ leadersΒ in growthΒ areas suchΒ as advancedΒ materials, photovoltaics, solid state lightingΒ andΒ biomedicalΒ devices. OurΒ immediateΒ aim is to build and maintain a portfolio of 15-20Β activeΒ projects at any point in timeΒ and toΒ begin toΒ advanceΒ one or twoΒ projects toΒ Stage 2 in 2009. We are well on our wayΒ toΒ achieving this goal.

The company is also involved inΒ a number ofΒ collaborative or grant funded programmes. Currently, theΒ Company is participating in a collaborativeΒ research and development project withΒ theΒ UniversityΒ ofΒ ManchesterΒ and the Centre for Process InnovationΒ in theΒ field of plastic electronics,Β sponsoring a Knowledge Transfer PartnershipΒ in photovoltaicsΒ with The University of Oxford, and hasΒ just been awardedΒ a grant from the Carbon Trust toΒ developΒ applications in solid state lighting.

Marcelo Bravo, Chief Executive of Oxford Advances Surfaces Group plc, said:

"I am delightedΒ to announce our first engagementΒ into the biomedical devices market. This market has great potential for us from general applications of the Ontoβ„’Β technology through to specialisedΒ biological coatings and biofilm and infection control."

Contacts:Β 

OxfordΒ Advanced Surfaces Group plc

Marcelo Bravo, Chief Executive

www.oxfordadvancedsurfaces.com

Tel:Β +44Β (0)1865 845807

Novum Securities Limited - Broker

Henry Turcan

Michael Brennan

Tel:Β +44 (0)20 7562 4700

Zimmerman Adams International - Nominated Adviser

Ray Zimmerman/Jonathan Evans

Tel:Β +44 (0)20Β 7398 2900

Notes to Editors

Oxford Advanced Surfaces Group plc

Oxford Advanced Surfaces Group plc develops and commercialises advanced materials and technology solutions leveraging breakthrough surface modification technology.

Ontoβ„’ technology exploits highly reactive chemistry allowing the rapid and convenient modification of the surface properties of a wide range of materials with a high degree of control over processing parameters. Ontoβ„’ can be applied using standard commercial coating and curing techniques and is a versatile, effective, yet simple approach to deliver intelligent advanced materials. This delivers permanent, dramatic and highly valuable changes to surface functionality.Β 

The company is working with commercial partners to develop applications in the industrial, consumer, electronics, alternative energy and biomedical sectors. OASG was originally spun out of Oxford University in the United Kingdom and is now listed on London's Alternative Investment Market (AIM).

Website:Β www.oxfordsurfaces.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCEAKESFFNPFFE
Date   Source Headline
5th Jan 20237:00 amRNSCancellation - DEEPMATTER GROUP PLC
4th Jan 20238:00 amRNSHolding(s) in Company
29th Dec 20225:30 pmRNSDeepmatter Group
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
19th Dec 20223:44 pmRNSResult of General Meeting
19th Dec 20222:05 pmRNSSecond Price Monitoring Extn
19th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 202211:05 amRNSSecond Price Monitoring Extn
19th Dec 202211:00 amRNSPrice Monitoring Extension
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:05 pmRNSSecond Price Monitoring Extn
15th Dec 20222:00 pmRNSPrice Monitoring Extension
9th Dec 202211:05 amRNSSecond Price Monitoring Extn
9th Dec 202211:00 amRNSPrice Monitoring Extension
8th Dec 20228:46 amRNSHolding(s) in Company
2nd Dec 20227:00 amRNSPosting of Circular
1st Dec 20227:00 amRNSProposed Cancellation of Ordinary Shares
24th Nov 20227:00 amRNSCorporate Update
31st Oct 202212:00 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading Update
26th Oct 20227:00 amRNSDeepMatter signs multi-year license agreement
26th Aug 20221:25 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHalf Year Results
28th Jun 20227:00 amRNSDeepMatter acquires AI specialist ChemIntelligence
20th Jun 20224:41 pmRNSSecond Price Monitoring Extn
20th Jun 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20222:05 pmRNSSecond Price Monitoring Extn
20th Jun 20222:00 pmRNSPrice Monitoring Extension
20th Jun 202211:05 amRNSSecond Price Monitoring Extn
20th Jun 202211:00 amRNSPrice Monitoring Extension
9th Jun 20225:26 pmRNSHolding(s) in Company
27th May 20222:30 pmRNSResult of AGM
25th May 20222:30 pmRNSIssue of Equity and TVR
23rd May 20227:00 amRNSDirectorate Change
20th May 20227:00 amRNSContract extension
11th May 20227:00 amRNSContract
27th Apr 20227:00 amRNSFinal Results
30th Mar 20224:00 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSContract
14th Feb 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20223:20 pmRNSHolding(s) in Company
26th Jan 20223:15 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 202212:30 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.